Compare KLA Corp. (KLAC) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Medpace Holdings Inc — how do they compare? KLA Corp. trades at $195.57 (market cap $256.72B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: KLA Corp. is far larger — about 15.3× Medpace Holdings Inc's market cap, and KLA Corp. pays a 0.47% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and Medpace Holdings Inc for 14 Days on average.
| KLAC | MEDP | |
|---|---|---|
Market Cap | $256.72B | $16.82B |
Volume | 9,970,753 | 223,093 |
Sector | Technology | Health |
52-Week High | $301.71 | $630.19 |
52-Week Low | $98.28 | $393.42 |
Typical Hold Time | 60 Days | 14 Days |
Enterprise Value | $257.97B | $16.44B |
Dividend Yield | 0.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $196.72, showing minimal daily movement with strong fundamental performance. The stock maintains bullish technical signals with support at $193 and resistance at $201. Recent earnings consistently beat expectations, with Q2 2026 EPS of $1.05 exceeding the $1.00 forecast. The company demonstrates robust profitability with 35.57% net income margin and 87.5% ROE, supported by AI-driven semiconductor equipment demand and a $12.57 billion backlog.
Outlook remains positive with analyst consensus target of $223.88 offering 14% upside potential. Key opportunities include AI infrastructure growth and advanced packaging demand, while risks involve competitive pressure from Applied Materials and ASML, along with execution challenges in meeting ambitious $26 billion revenue target by 2030. Institutional ownership trends show continued confidence with recent acquisitions by Envestnet Portfolio Solutions.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
